Biotech And Medical Stocks Leading Performers As 2022 Draws To A CloseInvestors Business Daily • 12/23/22
With Bear Market Scars, These 26 Stocks Expect Up To 1,220% GrowthInvestors Business Daily • 12/21/22
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)Business Wire • 12/21/22
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH MeetingBusiness Wire • 12/11/22
Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run?Zacks Investment Research • 12/05/22
Top Stocks In Multiple Industries Build Bases As Market Gains StrengthInvestors Business Daily • 12/02/22
Hot Biotech Stocks Rise Into Leadership; Pass Buy Points Or Build BasesInvestors Business Daily • 11/25/22
Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)Business Wire • 11/21/22
Can Genmab AS Sponsored ADR (GMAB) Run Higher on Rising Earnings Estimates?Zacks Investment Research • 11/17/22
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)Business Wire • 11/03/22
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)Business Wire • 10/28/22
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022GlobeNewsWire • 10/18/22